ANIK

Anika Therapeutics Inc. develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Headquartered in Bedford, Massachusetts, the company operates through two primary business segments: Joint Pain Management and Regenerative Solutions. Its Joint Pain Management portfolio includes MONOVISC and ORTHOVISC, viscosupplementation products that treat osteoarthritis knee pain, along with CINGAL, which combines hyaluronic acid with a steroid. The Regenerative Solutions segment offers products for bone preservation, nerve protection, and surgical applications, including TACTOSET calcium phosphate bone cement and HYALOFAST, a biodegradable support for cartilage regeneration. Anika sells its products in more than 20 countries through direct sales forces and distribution partners, serving orthopedic physicians, surgeons, and other healthcare providers. The company employs approximately 450 people globally and operates manufacturing facilities in the United States and Italy. Founded in 1983 and publicly traded since 1992, Anika has built its product platform primarily around hyaluronic acid technology. In recent years, the company expanded its regenerative medicine capabilities through strategic acquisitions, including the 2019 purchase of Parcus Medical, which added bone graft substitutes and regenerative tissue solutions to its portfolio. The company generates annual revenues exceeding $150 million, with international sales representing a growing portion of its business.